An updated patent review of dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors (2020-present).

Abdallah M, Keddis PM, Keddis TM, El-Gamil DS, Abadi AH, Kii I, Engel M, Abdel-Halim M

Open source

DOI
10.1080/13543776.2026.2694586
Published
2026 Aug
Container
Expert opinion on therapeutic patents
Publisher
Not recorded
Open access
unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1080/13543776.2026.2694586,
  title = {An updated patent review of dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors (2020-present).},
  author = {Abdallah M and Keddis PM and Keddis TM and El-Gamil DS and Abadi AH and Kii I and Engel M and Abdel-Halim M},
  year = {2026},
  journal = {Expert opinion on therapeutic patents},
  doi = {10.1080/13543776.2026.2694586},
  url = {https://doi.org/10.1080/13543776.2026.2694586}
}

RIS

TY  - JOUR
TI  - An updated patent review of dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors (2020-present).
AU  - Abdallah M
AU  - Keddis PM
AU  - Keddis TM
AU  - El-Gamil DS
AU  - Abadi AH
AU  - Kii I
AU  - Engel M
AU  - Abdel-Halim M
PY  - 2026
JO  - Expert opinion on therapeutic patents
DO  - 10.1080/13543776.2026.2694586
UR  - https://doi.org/10.1080/13543776.2026.2694586
ER  - 

APA

M, A., PM, K., TM, K., DS, E., AH, A., I, K., M, E., & M, A. (2026). An updated patent review of dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors (2020-present).. Expert opinion on therapeutic patents. https://doi.org/10.1080/13543776.2026.2694586

Source records